AGMB — Agomab Therapeutics NV Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Agomab Therapeutics NV, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -8.14 | -11.4 | -46.3 | -62.5 |
| Depreciation | ||||
| Deferred Taxes | ||||
| Non-Cash Items | -9.62 | -17 | -0.683 | 8.63 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | 1.44 | 4.34 | -0.189 | 1.96 |
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Other Liabilities | ||||
| Other Operating Cash Flow | ||||
| Cash from Operating Activities | -19 | -24.6 | -46.8 | -51.7 |
| Capital Expenditures | — | — | -0.675 | -0.004 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | -44.6 | 40 | 0 | -33 |
| Acquisition of Business | ||||
| Sale of Business | ||||
| Change in Net Investments | ||||
| Purchase of Investments | ||||
| Other Investing Cash Flow | ||||
| Cash from Investing Activities | -44.6 | 40 | -0.675 | -33 |
| Financing Cash Flow Items | -0.171 | -0.447 | -0.13 | 0 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 37.6 | 79.3 | 96.8 | -0.338 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -25.9 | 94.7 | 49.1 | -85 |